Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotre...
Will securing orphan status affect Aldeyra’s financing strategy, such as dilution risk from future equity raises or eligibility for orphan‑drug incentives?
How large is the addressable market for primary vitreoretinal lymphoma and what revenue upside could this orphan designation create for Aldeyra?
What are the anticipated timelines for further clinical development and potential FDA/EMA approval of ADX‑2191 following the orphan designation?
1 day ago